A Review of Recently Approved PD-1 Inhibitors for the Treatment of Gastric Cancer

Keru Chen

doi:10.47297/taposatWSP2633-456915.20230401

PDF
Export
Share
Collection
Album

A Review of Recently Approved PD-1 Inhibitors for the Treatment of Gastric Cancer

Volume 4, Issue 1

Views: 0 Downloads: 1

A Review of Recently Approved PD-1 Inhibitors for the Treatment of Gastric Cancer
College of Life Science of Sichuan Agricultural University,Sichuan,Ya'an,P.R. China,625014
Vol. 4, Issue 1, Pages: 91-96(2023)
DOI：10.47297/taposatWSP2633-456915.20230401

Full txt

Keru Chen. (2023). A Review of Recently Approved PD-1 Inhibitors for the Treatment of Gastric Cancer. Theory and Practice of Science and Technology, 4(1), 91-96.
DOI：

Keru Chen. (2023). A Review of Recently Approved PD-1 Inhibitors for the Treatment of Gastric Cancer. Theory and Practice of Science and Technology, 4(1), 91-96. DOI： 10.47297/taposatWSP2633-456915.20230401.

摘要

Abstract

Gastric cancer is a formidable adversary in the realm of human health

posing a serious threat to those who are afflicted by it. However

there is hope on the horizon as research into its treatment has been progressing steadily in recent years. Up to now

there are three kinds of immune checkpoint inhibitors approved by NMPA that can be used in treating Gastric cancer

all of which target PD-1. They are Sintilimab

Tislelizumab

and Nivolumab. While they share similarities in their approach to combating gastric cancer

there are also notable differences between them that warrant closer examination. This review highlights the cost-effectiveness of Sintilimab and Tislelizumab compared with Nivolumab. By analyzing these differences more closely

we can gain valuable insights into which drug may be most suitable for individual patients based on their unique circumstances. And with continued progress in this field

we can look forward to even more effective treatments being developed that will help us overcome this challenging disease once and for all.

关键词

Keywords

PD-1 inhibitorsGastric cancerNivolumabSintilimab

references

Yan, C., Shan, F., Ying, X., Li, Z. (2023). Global burden prediction of gastric cancer during demographic transition from 2020 to 2040. Chin. Med. J. (Engl.), 136: 397–406. [2] Hui, E., Cheung, J., Zhu, J., et al. (2017) .T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science, 355: 1428-+. [3] Smyth, E.C., Cervantes, A. (2020) .Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer. Esmo Open, 5: e001107. [4] Sunshine, J., Taube, J.M. (2015). PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23: 32–38. [5] Hofmeyer KA, Jeon H, Zang X. (2011) The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion. J. Biomed. Biotechnol., 451694. [6] Sundar, R., Cho, B.C., Brahmer, J.R., et al. (2015) .Nivolumab in NSCLC: latest evidence and clinical potential. Ther. Adv. Med. Oncol., 7: 85–96. [7] Hong, Y., Feng, Y., Sun, H., et al. (2021). Tislelizumab uniquely binds to the CC’ loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio, 11: 782–92. [8] Qiu, H.B. (2020). Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma. Thorac. Cancer, 11: 3419–21. [9] Guo, X., Yang, B., He, L., et al. (2022). PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis. Front. Immunol., 13: 905651. [10] Jiang, H., Zheng, Y., Qian, J., et al. (2020). Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer, 20: 760. [11] Jiang, H., Yu, X., Li, N., et al. (2022). Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J. Immunother. Cancer, 10: e003635.

Alert me when the article has been cited

Submit

No data

Related Author

No data

Related Institution

No data

⁰